The ArteraAI Prostate Test uses AI to analyze biopsy images and clinical data, predicting therapy benefits and long-term outcomes for localized prostate cancer. The DIRECT-AI registry will assess the ...

June 27th 2025. The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

In this interview, Patrick Soon-Shiong, MD, shares key updates in the development of nogapendekin alfa inbakicept-pmln (Anktiva), which was approved by the FDA in April 2024 for patients with ...

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

Specifically, the bill cuts funding for CDMRP from $1.509 billion in FY2024 to $650 million in FY2025. Prostate and kidney cancer research is currently funded at $110 million and $50 million, ...

As we know, there is never a one-size-fits-all for coding scenarios based on the reason for the visit. The correct code for reporting any office or other outpatient E/M service would be based on the ...

We identify a statistically higher odds of urethral stricture, genital numbness, and saddle sores (OR: 9.8, p<.001) in cyclists compared to swimmers/runners.Several other large studies corroborate ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

In this interview, Arpeet Shah, MD, considers some of the advancements and challenges that the field of urology will face in the coming year.Shah is a urologist at Associated Urological Specialists, ...

Michael J. Morris, MD, discusses the choice between the 2 FDA-approved PSMA-PET imaging agents—and piflufolastat F 18 (18F-DCFPyL; Pylarify) and Gallium 68 PSMA-11 (Ga 68 PSMA-11)—for managing ...

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) ...